Biomarkers in autoimmune rheumatic diseases

Autoimmune Rheumatic Diseases

1 Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Carrera 24 No. 63C-69, 111221 Bogota, Colombia 2 ZabludowitczCenter forAutoimmuneDiseases, ShebaMedical Center, Tel-Hashomer, Sackler Faculty ofMedicine, Tel AvivUniversity, 52621 Tel-Hashomer, Israel 3 Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Charitéplatz 1, 10117 Berlin, Germany 4...

MicroRNAs in autoimmune rheumatic diseases.

The etiology of autoimmune diseases remains largely unknown. In recent years, besides genetic factors, several studies proposed that the epigenome may hold the key to a better understanding of autoimmunity initiation and perpetuation. More specifically epigenetic regulatory mechanisms comprise DNA methylation, a variety of histone modifications, and microRNA (miRNA) activity, all of which act u...

Hypergammaglobulinaemia and autoimmune rheumatic diseases.

Biomarkers in Systemic Autoimmune Diseases

In an ideal scenario, a biomarker would both reveal the driver of disease and identify an effective treatment. In oncology, genetic biomarkers that molecularly or clinically classify patient populations for targeted therapies, e.g., BRAF [1] and HER-2 [2], have been clinically validated and are reaching this ideal. However, biomarkers are necessarily based on the pathobiology of the underlying ...

Pneumococcal vaccination in autoimmune rheumatic diseases

Streptococcus pneumoniae is the leading cause of the community-acquired pneumonia. The mortality rate of invasive pneumococcal infections is high. Immunocompromised patients suffering from autoimmune inflammatory rheumatic diseases (AIRD) have a high risk for acquiring these infections. Protection against infection can be improved with vaccination. After using polysaccharide vaccines (PPV-23), ...